ACRBP

Across TCGA pan-cancer cohorts, ACRBP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACRBP data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ACRBP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACRBP expression acts as an unfavorable survival marker, although some lineages such as SKCM and STAD show a favorable association.

LUSC, HNSC, and SKCM are the cancer types where ACRBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.181	0.660	.021	6	view →
HNSC	DFS	Median	All	0.132	0.625	.037	3	view →
SKCM	DFS	Median	II,III,IV	0.865	0.557	.022	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACRBP–LUSC (OS)

Open the LUSC breakdown →